- Investing.com
Metrics to compare | AZTR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAZTRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −18.5x | −0.5x | |
PEG Ratio | 0.00 | −0.02 | 0.00 | |
Price / Book | 1.1x | 6.4x | 2.6x | |
Price / LTM Sales | - | 7.8x | 3.3x | |
Upside (Analyst Target) | - | 56.2% | 47.7% | |
Fair Value Upside | Unlock | 10.5% | 6.6% | Unlock |
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.